Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BerGenBio ASA ( (BRRGF) ) has provided an update.
Oncoinvent ASA has completed a fully underwritten rights issue, raising NOK 130 million through the issuance of 260 million new shares, and has also issued 31,199,997 shares as underwriting commission. These changes have been registered with the Norwegian Register of Business Enterprises, resulting in a new share capital structure. This financial maneuver is expected to support Oncoinvent’s ongoing clinical trials and development of Radspherin®, potentially strengthening its market position in the biotechnology industry.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases in the peritoneum using radium-224, offering a unique therapeutic approach with promising early clinical efficacy data. The company operates a manufacturing facility in Oslo and is listed on the Oslo Stock Exchange.
Average Trading Volume: 574,372
Current Market Cap: NOK241.7M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.